CA3235348A1 - Compositions comprising ciprofloxacin and celecoxib - Google Patents

Compositions comprising ciprofloxacin and celecoxib Download PDF

Info

Publication number
CA3235348A1
CA3235348A1 CA3235348A CA3235348A CA3235348A1 CA 3235348 A1 CA3235348 A1 CA 3235348A1 CA 3235348 A CA3235348 A CA 3235348A CA 3235348 A CA3235348 A CA 3235348A CA 3235348 A1 CA3235348 A1 CA 3235348A1
Authority
CA
Canada
Prior art keywords
ciprofloxacin
celecoxib
tablet
tablet according
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3235348A
Other languages
English (en)
French (fr)
Inventor
Alon BEN NOON
Jeffrey Sterling
Oron Yacoby-Zeevi
Sharon COHEN VERED
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurosense Therapeutics Ltd
Original Assignee
Neurosense Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosense Therapeutics Ltd filed Critical Neurosense Therapeutics Ltd
Publication of CA3235348A1 publication Critical patent/CA3235348A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3235348A 2021-10-19 2022-10-18 Compositions comprising ciprofloxacin and celecoxib Pending CA3235348A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257130P 2021-10-19 2021-10-19
US63/257,130 2021-10-19
PCT/IL2022/051096 WO2023067592A1 (en) 2021-10-19 2022-10-18 Compositions comprising ciprofloxacin and celecoxib

Publications (1)

Publication Number Publication Date
CA3235348A1 true CA3235348A1 (en) 2023-04-27

Family

ID=85982158

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3235348A Pending CA3235348A1 (en) 2021-10-19 2022-10-18 Compositions comprising ciprofloxacin and celecoxib

Country Status (9)

Country Link
US (1) US12097185B2 (enExample)
EP (1) EP4419099A4 (enExample)
JP (1) JP7857044B2 (enExample)
KR (1) KR20240090519A (enExample)
CN (1) CN118369097A (enExample)
AU (1) AU2022370513B2 (enExample)
CA (1) CA3235348A1 (enExample)
IL (1) IL312274A (enExample)
WO (1) WO2023067592A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
EP3641820B1 (en) * 2017-06-20 2022-12-28 Neurosense Therapeutics Ltd. Compositions comprising an anti-inflammatory drug and a dicer activator for use in the treatment of neuronal diseases
US12527768B2 (en) * 2017-06-20 2026-01-20 Neurosense Therapeutics Ltd. Compositions comprising an anti-inflammatory drug and a dicer activator for use in the treatment of neuronal diseases

Also Published As

Publication number Publication date
US20230120880A1 (en) 2023-04-20
EP4419099A1 (en) 2024-08-28
US12097185B2 (en) 2024-09-24
IL312274A (en) 2024-06-01
AU2022370513A1 (en) 2024-05-16
CN118369097A (zh) 2024-07-19
EP4419099A4 (en) 2025-09-24
AU2022370513B2 (en) 2025-09-25
KR20240090519A (ko) 2024-06-21
JP2024539116A (ja) 2024-10-28
JP7857044B2 (ja) 2026-05-12
WO2023067592A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
US12357627B2 (en) Pharmaceutical compositions of cabozantinib
US20120015031A1 (en) Novel gastro-retentive dosage forms
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
WO2018106280A1 (en) Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
TW201442742A (zh) 祛鐵斯若（ｄｅｆｅｒａｓｉｒｏｘ）之口服配方
US20130344148A1 (en) Oral Composition
CZ20024216A3 (cs) Přípravky s chinolonovými antibiotiky s prodlouženým účinkem a způsob jejich výroby
JP2007520547A (ja) ベンラファキシン塩酸塩の徐放性コーティングされた小型錠剤
JP2022534159A (ja) 微細化した固形メラトニン組成物
EP1696889A1 (en) Pharmaceutical compositions of benzimidazole and processes for their preparation
US20100280035A1 (en) Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a ph modifier
WO2011064797A2 (en) Controlled release pharmaceutical compositions of galantamine
WO2009027786A2 (en) Matrix dosage forms of varenicline
CA3163555A1 (en) Methotrexate dosage form
AU2022370513B2 (en) Compositions comprising ciprofloxacin and celecoxib
JP2006507298A (ja) 経口持続放出型錠剤、ならびにその製造法および使用法
WO2023089553A1 (en) Controlled release formulations of flavoxate and process for preparation thereof
BR112024007727B1 (pt) Composições que compreendem ciprofloxacina e celecoxibe
HK40113418A (zh) 包含环丙沙星和塞来昔布的组合物
WO2013111147A1 (en) Extended release compositions of nevirapine

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241007

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241007

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251007

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251007